GenVec, Inc. (NASDAQ:GNVC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
GenVec, Inc. (the Company) announced today that it has effected a
one-for-ten reverse split (the Reverse Stock Split) of the
Companys outstanding shares of common stock, effective for
holders of record at the close of business on November 30, 2016.
To effectuate the Reverse Stock Split, the Company filed a
Certificate of Amendment to the Companys Amended and Restated
Certificate of Incorporation (the Amendment) with the Secretary
of State of the State of Delaware. to and upon the effectiveness
of the Amendment at 7:00 a.m., Eastern Standard Time, on December
1, 2016, each ten shares of the Companys common stock, par value
$0.001 per share, issued and outstanding at the time of such
effectiveness were reclassified and combined into one share of
common stock, par value $0.001 per share, of the Company.
The Company has retained American Stock Transfer Trust Company
(AST) to act as exchange agent for the Reverse Stock Split. AST
will manage the exchange of old, pre-Reverse Stock Split shares
for new post-Reverse Stock Split shares. Stockholders will
receive a letter of transmittal providing instructions for the
exchange of their shares. Stockholders who hold their shares in
street name will be contacted by their banks or brokers with any
instructions. For further information, stockholders and
securities brokers should contact AST at (877) 248-6417 or (718)
921-8317.
A copy of the Amendment is attached hereto as Exhibit 3.1 and is
incorporated herein by reference.
Section 8 Other Events
Item 8.01. Other Events.
On December 1, 2016, the Company issued a press release
announcing the effectiveness of the Reverse Stock Split discussed
under Item 5.03 of this report.
A copy of the Companys press release is attached hereto as
Exhibit 99.1 and is incorporated by reference herein.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 3.1 |
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of GenVec, Inc. |
|
| 99.1 |
GenVec, Inc. press release dated December 1, 2016, announcing the effectiveness of the Reverse Stock Split |
About GenVec, Inc. (NASDAQ:GNVC)
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. GenVec, Inc. (NASDAQ:GNVC) Recent Trading Information
GenVec, Inc. (NASDAQ:GNVC) closed its last trading session down -0.40 at 3.05 with 81,813 shares trading hands.
